Similar User
@SchreiberStuart
@kevansf
@adammgilbert911
@DennisWhom
@georg_e_winter
@ArrakisTx
@solutecarriers
@CovalentMod
@ArvinasInc
@Relay_Tx
@MilkaKostic
@myomnipod
@LynJonesChemBio
@Ginkgo
@JohnGHouston
Jnana announced today that it has entered into an agreement to be acquired by Otsuka Pharmaceutical. bit.ly/4ftndW9 #biotech #news
We're excited to share our most recent publication in the journal ACS Chemical Biology on a novel corrector for variants of SLC6A8 as a potential treatment approach for creatine transporter deficiency (#CTD). bit.ly/3YXaPrv @ACSPublications #raredisease #genetics
We’re at the @ESPKU Conference this week. Stop by our exhibit table, and don’t miss our poster presentation featuring efficacy and safety data from our Phase 1/2 study of JNT-517 in adults with #PKU. #ESPKU2024
We’re proud to share that Jnana is now part of Otsuka Pharmaceutical Co. and will operate as a direct subsidiary in Boston. We look forward to continuing our R&D efforts and advancing JNT-517 into a Ph 3 pivotal study for #PKU in 2025. bit.ly/3ZD6b2q #biotech
Today, we shared positive results from the Ph 1/2 clinical trial of JNT-517 in adults with phenylketonuria (PKU). Based on these results, we plan to advance JNT-517 directly into a pivotal Ph 3 study in early 2025. More: bit.ly/47fmynI #clinicaltrials #SSIEM #SSIEM2024
Attending #SSIEM2024? Join us on Thurs, 9/5 for a discussion on the potential for SLC6A19 inhibition as a treatment approach for PKU & other amino acid disorders. Thanks to presenters Cary Harding, MD, Nicola Longo, MD, Ania C. Munta, MD, & John Throup, PhD. #SSIEM
PKU is a rare inherited metabolic disease that can cause progressive and severe neurological impairment and neuropsychological complications. This year, Int’l PKU Day focuses on raising awareness about the lives of adults with PKU. More: bit.ly/3xxOFRJ #PKUDAY2024 #PKU
Our team joined the National PKU Alliance's Move Your Pheet for PKU challenge last month in honor of National PKU Awareness Month. We’ll help support the PKU community by strolling around the Seaport anytime! #PKU #raredisease @NPKUA_Info
At #BIO2024 this week? Caroline Stark Beer, our CBO, will be speaking on the panel “Exploring Deal-Making Options for Your Portfolio of Assets.” The panel will discuss biz dev opportunities across a range of deal structures. More: bit.ly/4bKgZPv #biopharma
Proud to support the National PKU Alliance and the PKU community. @NPKUA_Info
May is PKU Awareness Month. At Jnana, we aim to address the critical need for new treatments and are advancing JNT-517 in a clinical study in individuals with phenylketonuria. See the interim results from our ongoing study in #PKU: jnanatx.com/jnana-therapeu… #raredisease
Happy PKU Awareness month! Here's to a month of raising awareness, fostering understanding, and showing support for the PKU community.
Next week, CEO @JoanneKotz, PhD, will deliver a corporate presentation at the @rbccm Global Healthcare Conference on Tues, 5/14 at 2:05pm ET. More here: bit.ly/3JTgiam #healthcare
Our team members recently spent a day volunteering together at @Gr8BosFoodBank Currently, 1 in 3 Massachusetts residents face hunger, and we’re grateful for the opportunity to help make a difference in our community. #EndHungerHere
At the Society for Inherited Metabolic Diseases Annual Meeting next week, Jnana will present two posters on our SLC6A19 inhibitor program, including JNT-517, our first-in-class oral treatment in development for phenylketonuria (#PKU). @SIMDtweets bit.ly/3Q1ikJ4
CMO George Vratsanos, MD, will participate in a panel on “Innovation & Improvement: Bringing Forward the Next Wave of I&I Therapeutics” at the @GoldmanSachs Healthruption: 3rd Annual Healthcare Disruption Conference on April 9. #immunology #biotech
Heading to the @AmerChemSociety’s Spring 2024 Meeting? Don’t miss our oral presentation describing how RAPID, our next-gen chemoproteomics platform, enables the discovery of small molecule medicines for challenging-to-drug targets. bit.ly/3TkDpii #ACSSpring2024 #medchem
It’s @rarediseaseday, which raises awareness for the 300 million people living with a rare disease around the world. Our lead program is a potential 1st-in-class oral treatment for #PKU, a rare inherited metabolic disorder. Learn more: bit.ly/3TcX1WN #rarediseaseday
CEO @JoanneKotz, PhD., CMO George Vratsanos, MD., and CFO Doug Pagán will participate in 1:1 meetings at the @TDCowen 44th Annual Health Care Conference and Leerink Partners Global Biopharma Conference. bit.ly/3SXjbLk Will we see you there? #biotech #drugdiscovery
United States Trends
- 1. Travis Hunter 16,4 B posts
- 2. Clemson 7.556 posts
- 3. Colorado 71,6 B posts
- 4. Arkansas 28,4 B posts
- 5. Dabo 1.367 posts
- 6. Quinn 14,9 B posts
- 7. #SkoBuffs 4.462 posts
- 8. Cam Coleman 1.092 posts
- 9. Isaac Wilson N/A
- 10. #HookEm 3.263 posts
- 11. Zepeda 2.018 posts
- 12. Sean McDonough N/A
- 13. $CUTO 8.287 posts
- 14. Northwestern 6.867 posts
- 15. Tulane 2.880 posts
- 16. #NWSL N/A
- 17. Sark 1.978 posts
- 18. #iubb N/A
- 19. Pentagon 98,4 B posts
- 20. Mercer 4.322 posts
Who to follow
-
Stuart Schreiber
@SchreiberStuart -
Kevan Shokat
@kevansf -
Adam Gilbert
@adammgilbert911 -
Dennis X. Hu
@DennisWhom -
Georg Winter
@georg_e_winter -
Arrakis Therapeutics
@ArrakisTx -
Transporters and Solute carriers
@solutecarriers -
Covalent Modifiers
@CovalentMod -
Arvinas
@ArvinasInc -
Relay Therapeutics
@Relay_Tx -
Milka Kostić, PhD
@MilkaKostic -
Omnipod
@myomnipod -
Lyn Jones
@LynJonesChemBio -
Ginkgo Bioworks
@Ginkgo -
John Houston
@JohnGHouston
Something went wrong.
Something went wrong.